Source: Ruth Group Inc
NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- The Ruth Group, Inc., (TRG) a life science-focused strategic investor relations and public relations agency, today announced the formation of a specialized group focused on the gene therapy and gene editing sector.
The firm is forming the unit in recognition of the need for differentiated messaging and programs for these innovative and growing companies. Robert E. Flamm, Ph.D., Senior Vice President at TRG will head the new group, which will include team members with scientific, medical and capital markets expertise including Lee Roth, Senior Vice President of Investor Relations, Chris Nardo, Head of Capital Markets and Kristen Ko, Ph.D., Senior Account Executive.
“We are extremely pleased to launch this dedicated group to address the needs of companies in this emerging and transformative segment of healthcare,” said Carol Ruth, Founder and President of TRG. “TRG has a strong and growing roster of gene therapy and gene editing companies, and I am confident that we can further expand the practice under Robert and his team. As the field continues to grow, companies will require capital to expand and further develop their science. A major step to accomplishing this is to have clear messaging that effectively differentiate a company and its science from others in the space, and to deliver these messages to the right audiences. With our new gene therapy team, which includes both scientific communications and capital markets professionals, TRG is optimally positioned to bring tangible value to these companies.”
Dr. Flamm added, “Based on significant advances in the gene therapy and editing fields, highlighted by recent regulatory approvals and very positive FDA Advisory Committee meetings, the sector has attracted significant investment community and media interest. In our view, servicing these highly innovative but complex companies requires a combination of scientific, investor relations and public relations expertise dedicated to it. Our objective is to direct these skills toward our gene therapy and editing clients to provide superior service. We look forward to expanding this practice as we grow alongside our client companies.”
About The Ruth Group, Inc.
The Ruth Group (TRG) is a leading strategic communications firm focused exclusively on the healthcare industry. Founded in 1999, TRG provides investor and public relations counsel and services to a diverse group of innovative healthcare companies. We match the passion and commitment of our clients with dedicated teams focused on medical technology and tools/diagnostics, life sciences and healthcare services/HCIT. TRG’s strong track record of success has been achieved through our breadth and depth of healthcare expertise, deep Wall Street relationships, integrated PR capabilities and comprehensive team approach.
About Robert Flamm, PhD
Robert Flamm joined TRG in 2016. He develops and executes strategic investor relations programs for public and private healthcare companies. Robert's diverse background prior to joining TRG provides a unique perspective that can add additional value to clients, including over 13 years on Wall Street as a sell-side and buy-side analyst covering all sectors of healthcare across a wide range of market capitalizations. Robert trained as a neuroscientist through the post-doctoral level for 10 years. He holds a B.S. in Zoology from the University of Massachusetts in Amherst, a Ph.D. in Neurobiology and Behavior from Cornell University and an M.B.A. from Columbia University Business School.
Robert E. Flamm, Ph.D.
Retrieved from "http://globenewswire.com/news-release/2017/10/24/1152350/0/en/The-Ruth-Group-forms-Specialized-Team-Focused-on-Investor-and-Public-Relations-for-Gene-Therapy-Companies.html"